BOUNDLESS BIO, INC. Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount
BOUNDLESS BIO, INC. (BOLD) reported Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount of -$12.22 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-09.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate · last filed 2026-03-09
- BOUNDLESS BIO, INC. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2025 was -$12.22M.
- BOUNDLESS BIO, INC. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2024 was -$13.73M.
| Period end | Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount 12 month |
|---|---|
| 2025-12-31 | -$12.22M 10-K · filed 2026-03-09 |
| 2024-12-31 | -$13.73M 10-K · filed 2026-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| TALPHERA, INC. (TLPH) | United States | $0.060B | |
| CalciMedica, Inc. (CALC) | United States | $0.061B | -1.42 |
| Skye Bioscience, Inc. (SKYE) | United States | $0.061B | -0.48 |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Rein Therapeutics, Inc. (RNTX) | United States | $0.063B | -1.76 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| HYPERION DEFI, INC. (HYPD) | United States | $0.065B |